A Randomized, Double Blind, Placebo Controlled Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans Syndrome in Bilateral Lung and Single Lung Transplant Patients.
Phase of Trial: Phase III
Latest Information Update: 06 May 2017
At a glance
- Drugs Basiliximab (Primary)
- Indications Lung transplant rejection
- Focus Therapeutic Use
- 02 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Nov 2005 New trial record.